<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01206439</url>
  </required_header>
  <id_info>
    <org_study_id>UC- 09-12-31-04</org_study_id>
    <nct_id>NCT01206439</nct_id>
  </id_info>
  <brief_title>An Advanced Echocardiographic Evaluation of Nebivolol</brief_title>
  <official_title>An Advanced Echocardiographic Evaluation of Nebivolol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jack Rubinstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Nebivolol has any effect on heart function
      determined by changes in echocardiographic data or exercise tolerance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be given either 5 or 10 mg daily of oral Nebivolol for blood pressure control.
      They will undergo stress echocardiography at baseline, day 14, 90 and 180.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow enrollment
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Systolic and Diastolic Myocardial Function</measure>
    <time_frame>Baseline to day 180</time_frame>
    <description>Cannot report as only 1 patient was evaluated and data will not be able to remain anonymous.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise Tolerance</measure>
    <time_frame>Baseline to day 180.</time_frame>
    <description>Changes in exercise tolerance and time from baseline to 180 days.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Nebivolol 5 or 10 mg, oral, daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nebivolol</intervention_name>
    <description>nebivolol 5 or 10 mg oral, daily</description>
    <arm_group_label>Nebivolol 5 or 10 mg, oral, daily</arm_group_label>
    <other_name>Bystolic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of hypertension

          2. Written informed consent before initiation of any study related procedure

          3. Baseline Blood pressure &gt; 140 systolic or &gt;90 diastolic if on no antihypertensive
             therapy.

          4. Currently taking one antihypertensive or one antihypertensive and one diuretic for the
             treatment of hypertension.

        Exclusion Criteria:

          1. Physical limitations resulting in a limited ability to walk on treadmill for stress
             echo

          2. Intolerance to beta blockers

          3. On more than one medication for the treatment of hypertension unless the second
             medication is a diuretic.

          4. Currently pregnant or breast feeding.

          5. LFT &gt; 3 X ULN

          6. HgA1C &gt; 7

          7. Participation in other clinical research studies involving the evaluation of other
             investigational drugs or devices within past 30 days of enrollment

          8. Unwilling to follow protocol or return for study related procedures.

          9. Any of the following conditions:

             Coronary artery disease Heart failure Valvular heart disease Ischemic heart disease
             Atrial fibrillation Pacemaker ICD Hyperlipidemia Diabetes Mellitus Stroke/TIA Anemia
             COPD Asthma Renal failure requiring dialysis Liver failure Cirrhosis Thyroid
             dysfunction

         10. Any other medical condition that in the PI's opinion could affect myocardial function.

         11. Current ETOH or illicit drug abuse -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack Rubinstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2010</study_first_submitted>
  <study_first_submitted_qc>September 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2010</study_first_posted>
  <results_first_submitted>August 24, 2015</results_first_submitted>
  <results_first_submitted_qc>October 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2015</results_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Jack Rubinstein</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nebivolol 5 or 10 mg, Oral, Daily</title>
          <description>Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
nebivolol: nebivolol 5 or 10 mg oral, daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>subject did not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nebivolol 5 or 10 mg, Oral, Daily</title>
          <description>Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
nebivolol: nebivolol 5 or 10 mg oral, daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Systolic and Diastolic Myocardial Function</title>
        <description>Cannot report as only 1 patient was evaluated and data will not be able to remain anonymous.</description>
        <time_frame>Baseline to day 180</time_frame>
        <population>Insufficient data to analyze.</population>
        <group_list>
          <group group_id="O1">
            <title>Nebivolol 5 or 10 mg, Oral, Daily</title>
            <description>Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
nebivolol: nebivolol 5 or 10 mg oral, daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic and Diastolic Myocardial Function</title>
          <description>Cannot report as only 1 patient was evaluated and data will not be able to remain anonymous.</description>
          <population>Insufficient data to analyze.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Tolerance</title>
        <description>Changes in exercise tolerance and time from baseline to 180 days.</description>
        <time_frame>Baseline to day 180.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nebivolol 5 or 10 mg, Oral, Daily</title>
          <description>Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.
nebivolol: nebivolol 5 or 10 mg oral, daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jack Rubinstein</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-558-3062</phone>
      <email>rubinsjk@ucmail.uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

